Zenith Drugs Enterprise Value (EV)

Zenith Drugs Ltd Enterprise Value

The Zenith Drugs Ltd Enterprise Value is a key financial metric used by investors to evaluate Zenith Drugs Ltd's valuation, profitability, and overall financial performance. Tracking the Zenith Drugs Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.

Zenith Drugs Ltd (NSE: ZENITHDRUG, BSE: 92356) is currently trading at ₹39.95, with a market capitalization of ₹653.37M. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Zenith Drugs Ltd Enterprise Value is essential for fundamental analysis.

Zenith Drugs Ltd Enterprise Value Current Value

The current Zenith Drugs Ltd Enterprise Value stands at 0.

The Zenith Drugs Ltd Enterprise Value remains stable, indicating consistent financial performance.

Zenith Drugs Ltd Enterprise Value Historical Trend

The Zenith Drugs Ltd Enterprise Value has shown the following historical trend:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0
• 2020: 0

The decline in Zenith Drugs Ltd Enterprise Value indicates improving financial efficiency or better earnings growth.

What Zenith Drugs Ltd Enterprise Value Indicates for Investors

The Zenith Drugs Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.

This ratio is an important metric used in fundamental analysis of Zenith Drugs Ltd.

Zenith Drugs Ltd Enterprise Value Analysis Summary

The Zenith Drugs Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Zenith Drugs Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.

Regular tracking of Zenith Drugs Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.